LC determination of entacapone in tablets: In vitro dissolution studies

Journal of Chromatographic Science

Volumn 48, Issue 9, 2010, Pages 755-759

  Paim, Clésio S ^a   Martins, Magda T ^a   Malesuik, Marcelo D ^a   Steppe, Martin ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957976491     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.9.755     Document Type: Article

References (21)

1. K. Holm and C. Spencer. A review of its use in Parkinson's disease. Drugs 58 (1):159-177 (1999).
2. A. Gordin, S. Kaakkola, and H. Teräväinen. Clinical advantages of COMT inhibition with entacapone-a review. J. Neural Transm. 111 (10-11): 1343-1363 (2004).
3. FDA, Center for Drug Evaluation and Research. Guidance for Industry: Dissolution Testing of immediate Release Solid Oral Dosage Forms, Food and Drug Administration, Rockville, 1997.
4. D. Fortunato. Dissolution method.development for immediate release solid oral dosage forms. Dissol. Tech. 12 (3):12-14 (2005).
5. J. Skoug, D. Halstead, D. Theis, J. Freeman, D. Fagam, and B. Rohrs. Roteiro para Desenvolvimento e Validação do Teste de Dissolução em Formas Farmacêuticas Sólidas para Uso Oral. Pharm. Tech. 20:34-43 (1997).
6. M. Karlsson and T. Wikberg. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J. Pharm. Biomed. Anal. 10 (8):593-600 (1992).
7. T. Wikberg, A. Vuorela, P. Ottoila, and J. Taskinen. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. J. Drug. Metab. Dispos. 21:81-91 (1993).
8. P. Lehtonen, S. Lehtinen, LM Älkki-Laine, and T. Wikberg. Micellarelectrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine. J. Chromatogr. A 836 (1):173-188 (1999).
9. H. Keski-Hynnilä, R. Andersin, L. Luukkanen, J. Taskinen, and R. Kostiainen. Analysis of catechol-type glucuronides in urine samples by liquid chromatography-eletrospray ionization-tandem mass spectrometry. J. Chromatogr. A 794:75-83 (1998).
10. H. Keski-Hynnilä, K. Raanaa, J. Taskinen, and R. Kostiainen. Direct analysis of nitrocatechol-type glucuronides in urine by capillary electrophoresis-eletrospray ionization mass spectrometry and tandem mass spectrometry. J. Chromatogr. B 749 (2):253-263 (2000).
11. H. Keski-Hynnilä, K. Raanaa, M. Forsberg, P. Männistö, J. Taskinen, and R. Kostiainen. Quantification of entacapone glucuronide in rat plasma by on-line coupled restricted acess media column and liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 759 (2):227-236 (2001).
12. N. Ramakrishna, K. Vishwottam, S. Wishu, M. Koteshwara, and J. Chidambara. High-performance liquid chromatography method for the quantification of entacapone in human plasma. J. Chromatogr. B 823 (2):189-194 (2005). (Pubitemid 41116763)
13. K. Rajeswari, G. Sankar, A. Rao, and J. Rao. A new spectrophotometric method for the determination of entacapone in pure and tablet dosage form. Int. J. Chem. Sci. 4:694-696 (2006).
14. C Paim, H. Gonçalves, D. MironJ. Sippel, and M. Steppe. Stability-Indication LC determination of entacapone in tablets. Chromatographia 65 (9-10): 595-599 (2007)
15. The United States Pharmacopeia 31th ed. United States Pharmacopeial Convention: Rockville, United States of America, 2008.
16. J. Savolainen, J. Leppänen, M. Forsberg, H. Taipale, T. Nevalainen, J. Huuskonen, J. Gynther, P. Männistö, and T. Järvinen. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl-and N, N-dialkyl-carbamate esters of entacapone. Life Sci. 67 (2):205-216 (2000).
17. J. Leppänen, J. Huuskonen, J. Savolainen, T. Nevalainen, H. Taipale, J. Vesalainen, J. Gynther, and T. Järvinen. Synthesis of a water-soluble prodrug of entacapone. Bioorg. Med. Chem. Lett. 10 (17):1967-1969 (2000).
18. T. Heimbach, D. Oh, L. Li, M. Forsberg, J. Savolainen, J. Leppänen, Y. Matsunaga, G. Flynn, and D. Fleisher. Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res. 20 (6):848-856 (2003).
19. B. Rohrs. Dissolution method development for poorly soluble compounds. Dissol. Tech. 8 (3):51-56 (2001).
20. G. Shabir. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. J. Chromatogr. A 987 (1-2): 57-66 (2003).
21. FDA, Center for Drug Evaluation and Research. Reviewer Guidance: Validation of Chromatographic Methods, Food and Drug Administration, Rockville. 1994.